Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
Author:
Lars Lannfelt,Kaj Blennow,Henrik Zetterberg,Stellan Batsman,David Ames,John Harrison,Colin L Masters,Steve Targum,Ashley I Bush,Ross Murdoch,Janet Wilson,Craig W Ritchie
Publication:
The Lancet Neurology
Copyright © 2008 Elsevier Ltd. All rights reserved.